This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schellong, G. Articles by Rühl, U. Search for Related Content PubMed PubMed Citation Articles by Schellong, G. Articles by Rühl, U. Social Bookmarking                            What's this?

Salvage Therapy of Progressive and Recurrent Hodgkin’s Disease: Results From a Multicenter Study of the Pediatric DAL/GPOH-HD Study Group

From the Department of Pediatric Hematology and Oncology, University Children’s Hospital Münster, Münster; II. Children’s Hospital, HELIOS-Klinikum Berlin-Buch; University Children’s Hospital Kiel, Kiel; Division of Pediatric Hematology and Oncology, University Children’s Hospital Leipzig, Leipzig; Department of Pediatric Hematology and Oncology, University Children’s Hospital Tübingen, Tübingen; Department of Radiotherapy, Vivantes-Klinikum, Berlin-Moabit, Germany; St Anna Children’s Hospital, Vienna; Department of Radiotherapy and Radiobiology, University of Vienna, Vienna, Austria; and Department of Pediatric Hematology and Oncology, University Children’s Hospital Nijmegen, Nijmegen, the Netherlands

Address reprint requests to Günther Schellong, MD, Universitätsklinikum Münster, Kinderklinik, Pädiatrische Hämatologie und Onkologie, Albert-Schweitzer-Strasse 33, D-48129 Münster, Germany; e-mail: schellon{at}uni-muenster.de

PURPOSE: To evaluate a salvage therapy (ST-HD-86) for patients with progressive and relapsed Hodgkin’s disease after primary treatment in the pediatric DAL/GPOH studies. The essential chemotherapeutic regimens were ifosfamide, etoposide, and prednisone (IEP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

METHODS: One hundred seventy-six patients with progression (n = 51) or first relapse (n = 125) were enrolled by 67 centers. The median time from initial diagnosis to progression/relapse was 1.1 year (range, 0.1 to 15.3 years), and the patients’ median age was 14.7 years (range, 4.3 to 24.5 years). Salvage chemotherapy consisted of two to three cycles of IEP alternating with one to two cycles of ABVD supplemented in part by one to two cycles of cyclophosphamide, vincristine, procarbazine, and prednisone or lomustine (CCNU), etoposide, and prednimustine. Radiotherapy was given to involved areas using individualized doses. In the 1990s, additional high-dose chemotherapy with autologous stem-cell transplantation (SCT) was introduced for patients with unfavorable prognosis.

RESULTS: Disease-free survival (DFS) and overall survival (OS) after 10 years are 62% and 75%, respectively (SE, 4% each). Of 176 patients, 73 suffered second events. The risk-factor analysis revealed the time to progression/relapse as the strongest prognostic factor (P = .0001). Patients with progression have an inferior outcome (DFS, 41%; OS, 51%), whereas patients with late relapse (> 12 months after end of therapy) do well (DFS, 86%; OS, 90%), although none of them received SCT in second remission.

CONCLUSION: The result can be considered favorable. Whereas the salvage strategy for progressive disease has to be optimized further, it is possible to reduce intensity and avoid SCT in late relapses after Hodgkin’s disease in childhood/adolescence.

Supported by Deutsche Leukämieforschungs-Hilfe-Dachverband, Bonn, and Kinderkrebshilfe Münster, Germany.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?